A b s t r a c t
Copper is an essential element and a critical component of many metalloenzymes. However, excess copper, particularly the free (ie, not bound to proteins) fraction, may lead to tissue injury due to pro-oxidant effects and depletion of antioxidant reserves. It is estimated that less than 5% of the total copper concentration circulates independent of binding proteins such as ceruloplasmin. Thus, the concentration of protein-free copper is very low relative to the total serum copper concentration. As a result, a clinically significant change in the free copper concentration may not be detected through measuring total copper concentrations alone. Indeed, the total serum or plasma copper concentration is generally insensitive to detection of copper overload. 1, 2 The major circulating binding protein for copper is ceruloplasmin, and, hence, the total copper concentration in serum or plasma correlates to the concentration of ceruloplasmin. However, copper binds to other proteins such as transcuperin, albumin, and amino acids, and the total copper concentration in healthy people is reported to vary by 50 µg/dL (8 µmol/L) for a given ceruloplasmin concentration. 3 The most dramatic example of copper overload is Wilson disease (WD), wherein a defect in ATP7B, the gene that codes for the primary transporter responsible for copper elimination, leads to excess copper in circulation and accumulation of copper in tissues. Copper excess is also associated with cancer, preeclampsia, dilated cardiomyopathy, inflammation, biliary obstruction, Alzheimer disease, and total parenteral nutrition. 1, [4] [5] [6] [7] [8] The incidence of WD is estimated at 1:30,000. Clinical manifestations of WD are generally either hepatic or neurologic. Early diagnosis is important because WD can be treated and can be fatal if not treated. The diagnosis of WD is challenging and involves many laboratory and clinical tests.
Upon completion of this activity you will be able to:
• list clinical laboratory tests frequently used to diagnose Wilson disease.
• discuss clinical utility of measuring free vs total serum copper concentrations.
• describe limitations of calculating the free serum copper fraction vs measuring free serum copper concentrations directly.
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A typical algorithm for diagnosis includes ophthalmologic slit-lamp examination to detect the hallmark Kayser-Fleischer rings that reflect corneal copper deposition, ceruloplasmin quantification (typically low with WD), 24-hour urine copper quantification (typically elevated with WD), and hepatic copper quantification (typically elevated with WD). 5, 9, 10 While genetic testing for common mutations in ATP7B is available, there are more than 200 mutations associated with WD. Genetic testing is, therefore, useful only if the causative mutation(s) for the patient is detected by the testing performed. [10] [11] [12] Copper quantification of a liver biopsy specimen is considered diagnostic when the level is elevated but may be unreliable owing to the extreme heterogeneity in the hepatic distribution of copper. [13] [14] [15] Because copper is most toxic in the unbound form, measurement of unbound copper in circulation would theoretically be the most direct laboratory test for detecting potentially toxic copper overload. Copper concentrations in cerebrospinal fluid (CSF) have been useful for some patients, particularly with neurologic signs and symptoms. CSF concentrations of copper have been shown to be elevated in untreated WD and fall with treatment. 16, 17 However, collection of CSF is invasive and associated with some risk, making this specimen less than ideal for routine monitoring.
Serum free copper concentrations have historically been calculated, often cited as the copper index or non-ceruloplasmin-bound copper. The calculation is based on the total serum copper concentration less the product of the serum ceruloplasmin concentration and a factor correlating to the amount of copper bound per milligram of ceruloplasmin. A reference interval for the index is routinely identified as less than 10 µg/ dL (1.6 µmol/L).
Limitations of the calculated copper index include the assumption that ceruloplasmin is saturated, that ceruloplasmin and copper methods are not defined by the calculation, and that the proportion of copper bound to proteins other than ceruloplasmin is not considered in the calculation. Analytic methods for ceruloplasmin are known to produce variable results that will contribute to significant errors in the calculation of the copper index, making it unreliable and insensitive. 13, 18 Indeed, the calculation has been shown to generate mathematically negative (<0 µg/dL [0 µmol/L]) and elevated (>10 µg/dL [1.6 µmol/L]) results in the vast majority of healthy people. 3, 19 Direct measurement of the free copper concentrations in serum or plasma is a potential solution for these challenges and may provide a useful tool for the screening, diagnosis, and monitoring of WD. Methods for direct determination of free copper require separation of the protein-bound copper from the unbound (free) copper before detection. Previously published methods of separation include chelation, solid phase extraction, ultrafiltration, and microdialysis. 2, 4, [20] [21] [22] Although these methods demonstrate feasibility, and free concentrations of copper are elevated with WD, none of the methods has been validated as a clinical test. Herein, a method for direct determination of free copper concentrations in serum or plasma ultrafiltrate by inductively coupled mass spectrometry (ICP-MS) is described. Validation data and a reference interval for the use of this test clinically are also presented.
Materials and Methods
Ultrafiltration was performed with Centrifree Centrifugal Filter devices (Millipore, Bedford, MA), molecular weight cutoff of 30 kDa, and a centrifuge with a fixed angle rotor (2,000g, 20-40 minutes, ambient temperature). Reagents include phosphate-buffered saline; yttrium and copper stock solutions (Inorganic Ventures, Paterson, NJ); nitric acid (Fisher Scientific, Pittsburgh, PA); and National Institute of Standards and Technology (NIST) standard reference materials (SRMs) 1640, 1643d, and 1643e (National Institute of Standards and Technology, Gaithersburg, MD). Other supplies were purchased from Fisher Scientific.
The ceruloplasmin level was determined by turbidimetry (Roche P Modular, Basel, Switzerland). The protein concentration was determined using the micro BCA protein assay kit (Pierce Biotechnology, Rockford, IL). The copper level was determined using a PE Sciex 9000 or 6000 ICP-MS instrument (PE Sciex, Shelton, NJ) that was calibrated for copper (copper 65) for the range of 0.5 to 800 µg/dL (0.08-126 µmol/L). An aliquot of serum or plasma, ultrafiltrate, buffer, or NIST SRM was diluted 5× with type I water to which nitric acid (3.4 mol/L final concentration) and yttrium internal standard (1.12 µmol/L final concentration) were added and analyzed by ICP-MS. Samples were prepared using acid-washed polypropylene tubes in a controlled environment designed for trace elemental analysis.
Human plasma and serum samples were obtained from several sources. For preparation of samples used for precision, linearity, and accuracy experiments, fresh frozen plasma (FFP) was obtained from ARUP Blood Services (Salt Lake City, UT) and supplemented with copper. Residual serum or plasma specimens submitted to ARUP Laboratories for ceruloplasmin, free copper, or copper index determinations were also used. These specimens were deidentified according to institutional protocols and stored frozen (-70°C) until use. For the reference interval specimens, serum samples were obtained from 137 drug-free and healthy consenting adults (20-59 years old; 69 men) with royal blue-topped (no additive) or lavender-topped (EDTA) blood collection tubes according to protocols reviewed and approved by the University of Utah Institutional Review Board (Salt Lake City). Serum or plasma was separated from cells, transferred into acid-washed polypropylene storage tubes within 2 hours of collection, and stored frozen (-70ºC) until use. Similarly, specimens collected from patients with liver disease or WD were obtained with patient and/or parental consent following protocols reviewed and approved by the University of Utah Institutional Review Board.
Parametric statistics and least squares linear regression were determined with MS Excel (Microsoft, Redmond, WA). Differences were evaluated by using the Wilcoxon test or the Student 2-tailed t test for unpaired samples with unequal variance; statistical significance was defined when the P value was less than .01.
Results
The analytic measurement range was validated during several days between 0.5 and 800 µg/dL (0.08-126 µmol/L) with NIST SRMs and other purchased solutions of known copper concentration (y = 1.012x + 0.045; R 2 = 0.996; n = 133). Total imprecision, as expressed by the coefficient of variation (CV) was less than 5% at 800 µg/dL (126 µmol/L) and less than 15% at 0.5 µg/dL (0.08 µmol/L).
A major concern with any trace element analysis is the potential for external elemental contamination. Studies were performed to evaluate the potential for copper contamination originating from the Centrifree device by filtering phosphatebuffered saline (pH 6 and 8) and NIST SRMs and comparing copper results in ultrafiltrate specimens with copper concentrations determined before ultrafiltration. No statistically significant differences were observed between filtered and unfiltered samples, and recovery of NIST-defined target concentrations averaged 106% (SD = 8.2%).
To evaluate consistency between lots of Centrifree units, FFP was filtered using 3 different lots of the filtration devices. Between-day imprecision during 4 days with the 3 lots was reasonable for the low copper concentrations found in FFP (mean free copper level, 0.9 µg/dL [0.14 µmol/L]; total CV, 24%; n = 15). Filtration efficiency was evaluated by comparison of the protein concentration in 11 serum and plasma specimens with the protein concentration in corresponding ultrafiltrate specimens. An average of 98.4% (SD = 1%) of protein was removed by filtration for 20 minutes, consistent with manufacturer's claims.
The relationship between free copper, total copper, copper index, and ceruloplasmin in 50 residual patient specimens originally tested for ceruloplasmin is shown in zFigure 1z. A linear relationship between total copper and ceruloplasmin Direct free copper concentrations in 137 apparently healthy, drug-free, adult blood donors were determined for men and women zFigure 2z to establish a reference interval. No statistically significant differences between men and women were observed (P = .1274), although a trend to higher values in women was visually noted. The upper limit of a reference interval of 10 µg/dL (1.6 µmol/L) was determined based on the mean plus 2 SD, identical to the conventional reference interval. Nonparametric determination of the upper limit of normal, based on the 97.5 percentile, yielded similar results (10 µg/dL [1.5 µmol/L]).
To evaluate the potential clinical usefulness of free copper results, specimens were obtained from patients with suspected WD zTable 1z. Free copper was elevated in the patients with untreated WD and was within the reference interval for patients with treated WD.
Discussion
Free copper concentrations represent the active, potentially toxic fraction of copper in circulation. The most dramatic clinical example of copper overload is WD. Owing to impaired elimination of copper and resultant accumulation of copper observed with WD, it is logical that the concentration of free copper would be elevated, and determination of the free copper level may assist in the diagnosis and monitoring of WD. Herein, a method for the determination of the free copper concentration is presented and its validation for clinical use described.
Separation of bound and unbound fractions of copper was accomplished through ultrafiltration, using a molecular weight cutoff of 30 kDa. This cutoff should eliminate albumin, ceruloplasmin, and other proteins expected to bind copper. As such, the ultrafiltrate should contain only "free" copper that is easily measured using conventional ICP-MS. Concerns about the contribution of copper contamination from the filter units themselves and the loss of volume and apparent concentration of the specimen through the filtration process were not substantiated. Thus, recovery of known copper concentrations (NIST-traceable materials) was satisfactory. Although 3 lots of filter units were evaluated, it is possible that copper contamination could exist in other products or manufacturing lots. Careful validation of filter units is required. In addition, specimens should be collected only with tubes certified to be free of trace elements, and testing of any specimen for which the free copper concentration exceeds 10 µg/dL (1.6 µmol/L) should be repeated to verify that the result is not the consequence of filter damage or contamination. Calculated free copper concentrations, expressed as the copper index, have been proposed historically for use in the diagnosis and monitoring of WD. 3, 9, 13 The copper index is calculated from the ceruloplasmin and total copper concentrations. The calculated copper index estimation of free copper concentrations depends very much on the ceruloplasmin method. The calculated copper index also assumes saturation of ceruloplasmin binding with copper and that no other copper-binding proteins significantly influence the unbound fraction of copper. Previously it has been shown that the index does not accurately reflect actual free copper concentrations well. We also demonstrated, in a population of 333 people, that the index and direct measurement of copper in ultrafiltrate samples do not correlate.
To evaluate usefulness in the diagnosis and monitoring of WD, the data for patients with known diagnoses were studied and compared with the reference interval determined herein with apparently healthy white volunteers (20-59 years old). These data suggest a greater than 6-fold differential in the concentrations of free copper observed with disease compared with the reference population. Of interest, the free copper concentrations for patients with WD who had been treated fell within the reference interval. Results for directly determined free copper concentrations in samples from other patients analyzed by this method, but not formally enrolled in the validation study, also support the clinical usefulness of this test in the diagnosis and monitoring of WD. In contrast, free copper concentrations were not elevated for patients who may be at risk for copper overload owing to parenteral nutrition under conditions of biliary obstruction such as short bowel syndrome and sclerosing cholangitis. Larger numbers of patients would be required to determine the clinical sensitivity and specificity of this test. However, a specific and sensitive screen for WD could accelerate the diagnosis of WD and, when used to screen family members of patients with WD, may detect disease early enough to prevent the need for liver transplantation or the occurrence of debilitating neurologic or psychiatric symptoms. Free serum or plasma copper levels may also be useful in monitoring the treatment of WD because values for treated WD fall within the reference interval.
Free serum or plasma copper testing provides a much more accurate alternative to the calculated free copper index that may be useful for screening, diagnosis, and monitoring of WD.
